Free Trial

ProQR Therapeutics (PRQR) Competitors

ProQR Therapeutics logo
$1.99 -0.20 (-9.13%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$1.98 -0.01 (-0.50%)
As of 09/15/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRQR vs. SYRE, SPRY, PRAX, QURE, ATAI, CRON, CRMD, TSHA, IMNM, and AMLX

Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), Cronos Group (CRON), CorMedix (CRMD), Taysha Gene Therapies (TSHA), Immunome (IMNM), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

ProQR Therapeutics vs. Its Competitors

ProQR Therapeutics (NASDAQ:PRQR) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Spyre Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -238.52%. ProQR Therapeutics' return on equity of -61.25% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-238.52% -61.25% -28.13%
Spyre Therapeutics N/A -71.30%-38.69%

ProQR Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ProQR Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 302.01%. Spyre Therapeutics has a consensus price target of $53.40, suggesting a potential upside of 259.84%. Given ProQR Therapeutics' higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Spyre Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29

ProQR Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$20.46M10.23-$30.04M-$0.46-4.33
Spyre Therapeutics$890K1,007.12-$208.02M-$3.40-4.36

In the previous week, Spyre Therapeutics had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 4 mentions for ProQR Therapeutics. Spyre Therapeutics' average media sentiment score of 1.07 beat ProQR Therapeutics' score of 1.03 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProQR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Spyre Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ProQR Therapeutics beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRQR vs. The Competition

MetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$230.41M$3.15B$5.79B$10.18B
Dividend YieldN/A2.33%5.73%4.61%
P/E Ratio-4.3321.2474.8626.39
Price / Sales10.23466.65543.67125.97
Price / CashN/A44.4425.8129.91
Price / Book2.199.6413.256.28
Net Income-$30.04M-$53.20M$3.29B$270.38M
7 Day Performance-14.59%0.07%0.07%1.89%
1 Month Performance-2.93%4.27%4.60%6.01%
1 Year Performance8.74%9.62%72.95%25.26%

ProQR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRQR
ProQR Therapeutics
2.6342 of 5 stars
$1.99
-9.1%
$8.00
+302.0%
+7.6%$230.41M$20.46M-4.33180News Coverage
Positive News
Short Interest ↑
SYRE
Spyre Therapeutics
2.2599 of 5 stars
$16.63
-2.2%
$53.40
+221.1%
-49.5%$1.03B$890K-4.8973News Coverage
Positive News
SPRY
ARS Pharmaceuticals
2.6005 of 5 stars
$10.70
+6.3%
$32.50
+203.7%
-25.1%$995.18M$89.15M-21.8490
PRAX
Praxis Precision Medicines
2.4635 of 5 stars
$40.75
-13.0%
$85.88
+110.7%
-32.4%$985.99M$8.55M-3.32110Gap Down
High Trading Volume
QURE
uniQure
3.2082 of 5 stars
$17.43
-2.9%
$37.45
+114.9%
+162.2%$984.86M$27.12M-4.45500
ATAI
atai Life Sciences
2.876 of 5 stars
$4.52
-1.1%
$11.25
+148.9%
+257.7%$979.53M$2.31M-6.5580Positive News
CRON
Cronos Group
2.4881 of 5 stars
$2.48
-0.8%
N/A+17.0%$957.23M$117.61M49.60450
CRMD
CorMedix
3.9112 of 5 stars
$12.75
+2.8%
$17.33
+35.9%
+82.0%$925.65M$43.47M17.0030Analyst Upgrade
Insider Trade
TSHA
Taysha Gene Therapies
2.4719 of 5 stars
$3.24
-3.6%
$8.29
+155.7%
+31.9%$916.59M$8.33M-9.53180Positive News
Insider Trade
IMNM
Immunome
2.3212 of 5 stars
$9.40
-10.6%
$22.89
+143.5%
-40.6%$915.71M$9.04M-3.0540Positive News
AMLX
Amylyx Pharmaceuticals
2.1984 of 5 stars
$10.44
+2.4%
$12.25
+17.3%
+352.3%$909.51M$87.37M-4.18200Positive News
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:PRQR) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners